These data suggest that KhkC KO, and to similar extent KhkA/C KO, impairs Kras/MAPK and mTORC pathway gene expression and the activation of ERK1/2 and RPS6, rewires the expression of PDAC-related metabolism and signaling pathways, thereby impairing tumor progression. The gene discussed is KRAS; the disease is neoplasm.